Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole vs Olanzapine for Weight Change in Schizophrenia
NCT00095524Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2004
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole in schizophrenia and schizoaffective disorder (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change from baseline in body weight at 16 weeks. Started Mar 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00095524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095524.